Daily non-political popular news in brief.
Circumcision for prevention of HIV: new analysis demonstrates cost-effectiveness
12-25-2006 · EurekAlert!A team of researchers who conducted a landmark trial in Orange Farm, South Africa, which concluded that male circumcision can substantially reduce the risk of becoming infected with HIV, have now studied the economic aspects of this approach to preventing HIV/AIDS. Their new research, published in PLoS Medicine, suggests that circumcision could reduce the cost of health care in South Africa (and other sub-Saharan Countries), mainly through savings on the cost of HIV treatment.
Read more »
Keywords: circumcision, prevention, hiv, analysis, demonstrates, cost-effectiveness, analysi, demonstrate, cost, effectiveness
« Previous | Next »
Similar news on "Circumcision for prevention of HIV: new analysis demonstrates cost-effectiveness":
- Targeted HIV testing more effective than CDC mass testing proposal
06-11-2007 · EurekAlert!
A targeted campaign of testing and counseling aimed at those who are at high risk for HIV would be more effective than the mass patient screening proposed by the Centers for Disease Control and Prevention, according to an analysis by David Holtgrave, Ph.D., an expert on HIV prevention at the Johns Hopkins Bloomberg School of Public Health. Holtgrave's study is the first to examine the cost-effectiveness of the CDC's testing plan.
Similar news · Read more »
- Scaling up HIV prevention programs is cost effective
07-11-2007 · EurekAlert!
Scaling up HIV prevention programs can increase efficiency and thus prevent more HIV infections, according to a study published in the online open access journal BMC Health Services Research. Each doubling of a program's scale can reduce costs by around a third, and some large programs are ten times more efficient than smaller ones -- meaning that many more infections are averted for the same amount of resources.
Similar news · Read more »
- Leading advocates express support for microbicide research, despite disappointing trial results
01-31-2007 · EurekAlert!
HIV prevention advocates from three major civil society organizations today emphasized the importance of continued research into new HIV prevention options, despite the recent discontinuation of the phase III effectiveness trials of the microbicide candidate, cellulose sulfate (CS).
Similar news · Read more »
- Enhanced depression care may be cost-effective for employers
12-04-2006 · EurekAlert!
Offering additional depression screening and care may save employers about $3,000 per 1,000 workers over five years, according to a cost-effectiveness and cost-benefit analysis reported in the December issue of Archives of General Psychiatry, one of the JAMA/Archives journals.
Similar news · Read more »
- Cost-effectiveness of ligation vs. beta-blockers in the prevention of variceal bleeding
04-02-2007 · EurekAlert!
Endoscopic variceal ligation is cost-effective relative to beta-blockers for the prevention of variceal bleeding in cirrhotic patients if quality of life-years are considered. If only life-years are considered, then endoscopic variceal ligation is not cost-effective.
Similar news · Read more »
- MedImmune to present RSV surveillance and cost-effectiveness data at American Academy of Pediatrics
10-26-2007 · EurekAlert!
MedImmune, Inc., today announced it will present three abstracts at the American Academy of Pediatrics 2007 National Conference & Exhibition, adding to the company's growing body of research into the prevention of respiratory syncytial virus, a leading cause of hospitalization among infants.
Similar news · Read more »
- MedImmune presents new pharmaco-economic data at AAP regarding infants at high risk for RSV
10-29-2007 · EurekAlert!
MedImmune today announced results from a recent economic analysis of Synagis (palivizumab), a monoclonal antibody that is the standard of care for prevention of severe lower respiratory tract infection due to respiratory syncytial virus in high-risk infants. Released at the American Academy of Pediatrics 2007 National Conference and Exhibition, the analysis evaluated the costs of providing Synagis to premature infants, as well as the potential health benefits and cost savings that could occur from lower rates of severe RSV infections.
Similar news · Read more »
- Investment level in HIV prevention programs related to HIV incidence in the United States
01-30-2007 · EurekAlert!
Researchers at Johns Hopkins Bloomberg School of Public Health conducted a historical analysis to examine the relationship between the Centers for Disease Control and Prevention's (CDC) HIV prevention budget and HIV incidence in the U.S. from 1978 to 2006. The results are published in the January 2007 edition of the American Journal of Preventive Medicine.
Similar news · Read more »
- Preclinical results of Geovax's AIDS vaccines demonstrate potential to protect against disease
02-06-2007 · EurekAlert!
GeoVax Labs, Inc., an Atlanta-based biotechnology company, today reported successful results from a preclinical trial using GeoVax's vaccines for the therapeutic treatment and prevention of Acquired Immunodeficiency Disease Syndrome ("AIDS") in non-human primates. The data demonstrate the effectiveness of GeoVax's DNA/MVA vaccines in controlling the Simian ("SIV") AIDS virus through immune responses raised by the vaccines. These promising results have resulted in preliminary plans to conduct human therapeutic studies utilizing GeoVax's vaccines.
Similar news · Read more »
- Male circumcision for HIV prevention and more
07-23-2007 · EurekAlert!
Three clinical trials in Africa found that adult male circumcision reduced the risk of men acquiring HIV infection from heterosexual sex by 51-60 percent. While adult male circumcision may also have a role to play in preventing HIV transmission in the US, say scientists at the US Centers for Disease Control in a paper in PLoS Medicine, "the extent of this role on a population basis is unknown."
Similar news · Read more »
